SAN CARLOS, Calif., Oct. 11, 2016 /PRNewswire/ -- Rosa & Co. LLC, the worldwide commercial leader in PhysioPD™ Research, today announced their participation and poster presentation at ACoP7 to be held in Bellevue, WA on October 23-26, 2016. The conference will bring together leading researchers, academics, clinicians and educators to foster discussion and exchange of experiences, ideas, and visions to promote pharmacometrics research and methodology globally.
Dr. Christina Friedrich, Chief Engineer, PhysioPD at Rosa, will present a poster entitled "A Quantitative Systems Pharmacology Platform of Brain and Serum Progranulin (PGRN) to Investigate Targets in Frontotemporal Dementia (FTD)" on Monday, October 24th, 2016 at 7:30am to 9:30am. The poster will demonstrate how the PGRN PhysioPD Research Platform has been used to improve understanding of PGRN production dynamics, generate new hypotheses to explain conflicting data, and evaluate the potential effects of modulating different targets and model drug effects on increasing PGRN for the treatment of FTD.
PhysioPD, Rosa's brand of Quantitative Systems Pharmacology (QSP), is a proven and powerful research approach that enables unique scientific insight and informs decisions from early discovery through clinical development. The most innovative R&D organizations in the industry are increasingly adopting PhysioPD Research as an essential research component for more informed decision-making. Rosa's participation in this conference further demonstrates its commitment to expanding the adoption of PhysioPD into a standard research method used within the pharmaceutical industry.
"We are pleased to share the groundbreaking work from our PhysioPD Research and are honored that Dr. Friedrich's presentation was accepted for inclusion in the ACoP 2016 meeting."
-Dr. Ron Beaver, Founder & CEO, Rosa & Co. LLC
Rosa supports clients with their significant research decisions – from preclinical through clinical development – by creating and utilizing customized PhysioPD™ Research Platforms to elucidate the connection between drug and disease mechanisms and ultimate patient outcomes. The PhysioPD Platforms are used to research and simulate normal and disease physiology, drug action, patient variability, and trial outcomes. Rosa's clients are involved in Platform creation, qualification, and biological simulation research. Clients retain the PhysioPD Platforms to support future research and program decisions. Rosa's staff has unparalleled professional experience applying biological modeling and simulation research to support drug development and has over 13 years of client engagements in virtually all therapeutic areas. Rosa is unique in its breadth and depth of therapeutic area experience, including metabolism, immuno-oncology, oncology, cardiovascular, inflammation, immune dysfunction, central nervous system, dermatology, rare disease and antibacterial/antiviral biology. For more information, visit http://www.rosaandco.com/news.html.
Rosa, the Rosa logo, and PhysioMap are registered trademarks and PhysioPD is a trademark of Rosa & Co. LLC.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rosa--co-to-present-research-results-at-the-2016-american-conference-on-pharmacometrics-acop-300342432.html
SOURCE Rosa & Co. LLC